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Ornithine decarboxylase activity as a marker of premalignancy in the
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A i m.  There is no biochemical marker of premalignancy known to antedate the appearance of histological changes in the gut
epithelium. Although increased ornithine decarboxylase (ODC) activity has been described as a marker of neoplastic
potential, studies based on large material to assess the value of its measurement have not been reported. The aim of this study
was to determine mucosal ODC activities in patients with premalignant and malignant conditions of the GI tract and to try
to identify high risk patients.
M a t e r i a l  a n d  m e t h o d s. Mucosal biopsy samples were obtained during endoscopy from 221 patients. ODC activity was
measured using a L-[14C]-ornithine bioassay and results were expressed in pmol/mg protein/hour. Conventional histology was
used to detect the presence of dysplasia, which was graded according to established criteria.
R e s u l t s.  ODC activity was significantly higher in all premalignant and malignant conditions than in normal tissues.
However, our results have shown that high ODC activity does not always indicate malignancy and low activity does not exclude
the increased neoplastic potential. We did not observe significant differences related to the degree of dysplasia in the
epithelium.
C o n c l u s i o n.  Inability to differentiate premalignant conditions from cancer indicates that ODC bioassay is not a valuable
marker of increased neoplastic potential.
AktywnoÊç dekarboksylazy ornityny jako marker zmian przedrakowych w przewodzie pokarmowym
C e l.  Dotychczas nie ma biochemicznego markera przemiany przedrakowej, który poprzedza pojawienie si´ zmian
histopatologicznych w b∏onie Êluzowej. Chocia˝ uwa˝ano, ˝e takim markerem mo˝e byç podwy˝szona aktywnoÊç
dekarboksylazy ornityny (ODC), nie by∏o dotychczas przekrojowych badaƒ, przeprowadzonych na ró˝norodnym materiale,
które potwierdzi∏yby przydatnoÊç oznaczeƒ tego enzymu. Celem pracy by∏o okreÊlenie aktywnoÊci ODC w b∏onie Êluzowej
u chorych ze zmianami przedrakowymi i rakami przewodu pokarmowego oraz próba identyfikacji osób z wysokim ryzykiem
nowotworowym.
M a t e r i a ∏  i m e t o d a.  Zbadano 221 wycinków b∏ony Êluzowej pobranych w czasie badania endoskopowego. AktywnoÊç
ODC oznaczano za pomocà metody enzymatycznej z u˝yciem L-[14C]-ornityny, a wyniki przedstawiano w pmol/mg
bia∏ka/godz. Histopatologicznie okreÊlano stopieƒ dysplazji w badanych gruczolakach.
W y n i k i.  AktywnoÊç ODC by∏a znamiennie wy˝sza we wszystkich stanach przedrakowych i rakach w porównaniu do
prawid∏owej b∏ony Êluzowej. Jednak wyniki badaƒ wskazujà, ˝e wysoka aktywnoÊç enzymu nie zawsze wskazuje na istnienie
nowotworu z∏oÊliwego, a niska aktywnoÊç nie pozwala wykluczyç zwi´kszonego ryzyka nowotworowego. Nie stwierdzono
istotnych ró˝nic w aktywnoÊci ODC w zale˝noÊci od stopnia dysplazji w nab∏onku.
W n i o s e k.  Niemo˝noÊç odró˝nienia stanów przedrakowych i raków wskazuje, ˝e aktywnoÊç ODC, oznaczana metodà
enzymatycznà, nie mo˝e byç uznana za przydatny marker zwi´kszonego ryzyka przemiany nowotworowej w przewodzie
pokarmowym.
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Introduction
Ornithine decarboxylase is the first and also the rate-
limiting enzyme in the polyamine pathway and, therefore,
a key regulatory enzyme in growth processes [1]. It
converts ornithine to putrescine. ODC induction and
putrescine accumulation occur in phases G1 and G2 of
the cell cycle, whereas spermine and spermidine accu-
mulate in phase S, together with RNA and DNA synthesis
[2, 3]. Thus, changes in ODC activity reflect the rate of
macromolecular synthesis. Sustained high ODC levels
have been implicated as an essential component of
tumour development and elevated levels have been found
during neoplastic transformation. ODC activity in tumour
tissue is generally several times higher than in the
surrounding normal tissue or within inflamed areas [4,
5]. Preliminary studies have suggested that ODC activity
can be a useful marker of neoplastic potential, being
altered in certain premalignant conditions of the
gastrointestinal tract. Increased ODC activity was found
in the colonic mucosa in familial adenomatous polyposis
(FAP). This increase was relatively slight in morpho-
logically normal mucosa, but rose progressively in
adenomatous polyps [6]. Among the FAP patients rectal
ODC activity seemed to decrease in time after colon
resection and ileorectal anastomosis [7, 8]. High ODC
levels were reported in patients with sporadic colorectal
adenomas, both in tumours and in morphologically
normal mucosa [9, 10]. Moreover, some studies have
suggested, that there is an important correlation between
the activity of the enzyme and the presence of dysplasia in
the epithelium. ODC levels were higher in the dysplastic
Barrett's oesophageal mucosa than in the columnar
epithelium without dysplasia [11, 12]. This data, usually
based on small groups of patients, has not been confirmed
in the course of studies based on large and varied clinical
material.
We have examined 221 endoscopic biopsy specimens
obtained from individuals with a variety of upper and
lower gastrointestinal conditions known to predispose to
malignancy, such as gastric atrophy in pernicious anaemia,
chronic superficial and atrophic gastritis, previous gastric
surgery, sporadic gastric, duodenal and colonic adeno-
matous polyps, familial adenomatous polyposis and
extensive ulcerative colitis. We have performed 663
measurements (all assays were done in triplicate) to
determine the relative activity of ODC in these tissues
in comparison to normal controls and gastrointestinal
cancers. In order to correlate ODC activity with the
degree of dysplasia simultaneous biopsy specimens for
histological grading were taken.
Material and methods
U p p e r  G I  t r a c t  s t u d i e s
We studied biopsy specimens taken from control subjects
(n=26), who had upper abdominal symptoms but normal upper
GI endoscopy, subjects with chronic superficial gastritis (n=15),
chronic atrophic gastritis (n=10), pernicious anemia (n=5),
operated stomachs (partial gastrectomy, vagotomy and
pyloroplasty) (n=20), gastric adenomas (n=15) and duodenal
adenomas (n=15). Biopsies from proven gastric cancers (n=15)
and cancers of the major duodenal papilla (n=10) were used as
positive controls.
C o l o r e c t a l  s t u d i e s
We studied biopsies from normal individuals, who were judged
by the clinician to have functional symptoms and who had
normal investigation results (including sigmoidoscopy or
colonoscopy and biopsy – n=12), patients with extensive
ulcerative colitis lasting longer than 10 years, currently active
or quiescent (n=20), individuals with FAP (n=11) and
adenomas (n=30). The extent and activity of ulcerative colitis
were assessed using clinical, colonoscopical and histological
criteria. Patients with FAP were studied before total colectomy.
No colon cancers were found in the surgical specimens obtained
from these patients. All studied sporadic adenomas were
removed by endoscopic snare polypectomy. Colon cancer
biopsies (n=17) served as positive controls.
H i s t o p a t h o l o g i c a l  s t u d i e s
The type of gastritis was based on the updated Sydney system
[13]. In patients with ulcerative colitis an additional biopsy
specimen was obtained from a site adjacent to that used for the
ODC assay for histological grading of the degree of inflamation
[14]. In patients with colonic adenomas dysplasia was evaluated
and graded according to the generally accepted system described
as low-, medium- or high-grade dysplasia [15]. The person
grading specimens was blinded as to the ODC results.
O D C  a s s a y
Mucosal ornithine decarboxylase was assayed using a method
previously described [16, 17]. Mucosal specimens were
homogenised immediately at the endoscopy unit using Polytron
PT1200 (Kinematica AG) in 300 ul of buffer containing 50 mM
Hepes-NaOH (pH 7.5), 2.5 mM dithiothreitol (DTT), 0.25 mM
pyridoxal 5-phosphate and 0.1 mM EDTA. Supernatants were
frozen in -70°C until the ODC assay was performed. The
reaction mixture consisted of 20 ul of homogenate, 0.25 mM
pyridoxal 5-phosphate, 2.5 mM DTT, 50 mM Hepes-NaOH
(pH 7.5), 0.1 mM EDTA with 0.2 uCi of L-[14C]-ornithine
hydrochloride (Amersham International) in a total volume of
40 ul. The reaction tube was sealed with a plastic tip in which was
embedded a 1.0 x 4.0 cm. square of Whatman no 1 filter paper
soaked with 40 ul of beta-phenylethylamine. Tubes were
incubated at 37°C for 60 minutes and the reaction was then
stopped by adding 200 ul of 2 M citric acid. After further 60
minutes of incubation, the filter paper was removed, placed in 10
636
Key words: ornithine decarboxylase (ODC), polyamines, premalignant conditions in the gastrointestinal tract, markers
of premalignancy
S∏owa kluczowe: dekarboksylaza ornityny (ODC), poliaminy, stany przedrakowe w przewodzie pokarmowym, markery
przednowotworowe
ml of scintillation liquid and counted in a Beckman's LS 6000 IC
scintillation counter. Results were expressed as pmol of [14C]O2
released per hour per mg of tissue protein. The protein
concentration of the homogenate was measured using the Bio-
Rad Protein assay. All assays were performed in triplicate and
included negative controls.
S t a t i s t i c a l  a n a l y s i s
Results were presented as medians and interquartile ranges.
Differences between groups were assessed by analysis of variance
(ANOVA) and were considered to be significant if p<0.05.
Results
U p p e r  G I  t r a c t  s t u d i e s
Median mucosal ornithine decarboxylase activity was
similar in the normal stomach (164, interquartile range
(IQR) 108-270 pmol/mg protein/h) and in the duodenum
(121, IQR 41-300 pmol/mg protein/h). ODC activity was
significantly higher in biopsies from all studied pre-
malignant conditions than in those from normal tissues,
both in the stomach and the duodenum (Figure 1 and
Figure 2). Although increased ODC activity was noted
in patients with gastritis (652, IQR 446-1023 pmol/mg
protein/h), no significant differences were observed
regarding the type of inflammation (gastric atrophy in
pernicious anaemia, chronic superficial or atrophic
gastritis – Table I). Subjects, who had undergone gastric
surgery 10 years prior to the study, had ODC activities
similar to those observed in subjects with gastric or
duodenal adenomas (1204, IQR 776-3213 vs 896, IQR
481-2543 and 1176, IQR 358-1336 pmol/mg protein/h,
respectively). However, because of an overlap between
the studied groups, ODC activity in the premalignant
conditions did not differ signifficantly from that found
in confirmed cancers (p>0.05).
C o l o r e c t a l  s t u d i e s
Median ODC activity in the normal colonic mucosa was
185 (IQR 41-300) pmol/mg protein/h. This activity was
significantly elevated in the adenomatous polyps (1423,
IQR 804-2198), familial adenomatous polyposis (929,
IQR 75-1329), as well as in extensive ulcerative colitis
(526, IQR 178-1309). However, because these results
partly overlapped with those found in confirmed colon
cancers (3582, IQR 1599-4654), high ODC activities did
not always indicate premalignancy and low activities could
not exclude an incresed neoplastic potential (Figure 3).
When subjects with ulcerative colitis were stratified
into groups according to the clinical activity of the disease,
a significant difference was recorded (Table II). There
was no correlation between ODC acivity and the degree
of dysplasia in the colonic adenomatous polyps
(Table III).
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Figure 1. ODC activity in premalignant gastric conditions and gastric
cancers in comparison to normal mucosa (medians with IQR)
Figure 2. ODC activity in duodenal adenomas and cancers of the
papilla of Vater in comparison to the normal duodenal mucosa
(medians with IQR)
Table I. ODC activity in individuals with pernicious anaemia, 
chronic atrophic gastritis and chronic superficial gastritis 
(in pmol/mg protein/h)
Type of gastritis Number Median Interquartile 
range
Gastric atrophy in 5 957 420-1478
pernicious anaemia
Atrophic gastritis 10 1004* 597-1187
Superficial gastritis 15 1136* 430-1786
* p>0.05 compared to median in gastric atrophy in pernicious anaemia
Figure 3. ODC activity in colonic premalignant conditions and cancers
in comparison to normal mucosa (medians with IQR)
Discussion
An ideal marker of proliferation and malignancy should
be universal and should appear early in the cell cycle. Its
level should increase simultaneously with proliferation
and decrease when growth rates decline. It should be
easily monitored and reflect rapid changes in proli-
feration. An optimal marker should also have a short
half-life time permitting the assessment of growth arrest
when the marker decays. Ornithine decarboxylase seems
to be universal and fulfills these requirements. This
enzyme appears during phase G1 of the cell cycle and
has an extremely short half-life (15-20 min) [3]. Changes
in ODC activity correspond well with other growth
parameters, although measurements are somewhat time-
consuming and complicated for routine use. Initial studies
performed on tissues of the human gastrointestinal tract
were encouraging and suggested that ODC activity could
be an accurate indicator of increased neoplastic potential
[18, 19, 20]. There were reports of significant increases
of this enzyme activity in colonic adenomas compared
to normal-appearing tissue [9]. Rectal mucosal ODC
activity has been shown to be higher in symptomatic
patients with familial adenomatous polyposis than in
asymptomatic family members. It was also elevated in
abnormal polypoid mucosa, as compared with normal
colon of FAP individuals [6]. Increased ODC activity
found in dysplastic Barrett's epithelium suggested that it
might be a useful marker for upper gastrointestinal tract
malignancy [11, 12]. However, more recent studies were
less optimistic. The importance of elevated ODC activity
has been questioned mainly because of the overlap
between normal and abnormal mucosal activities [21, 22].
Large inter-individual variations in the magnitude of
increased enzyme activity were observed in the same
gastrointestinal tumors. Some variations might be caused
by intrinsic sampling problems [23, 24]. Although
literature on ODC and polyamines is extensive, there
have been no longitudinal studies to assess the serial use
of these measurements and their predictive value in the
gastrointestinal malignancy.
In this study, we assessed the value of ODC activity
as a potential marker of malignant risk both in the upper
and lower gastrointestinal tract by comparing measu-
rements in the normal epithelium, three types of proven
cancers and in eight conditions that are known to
predispose to malignancy. 221 mucosal biopsy samples
were immediately homogenized in the endoscopy unit
and stored at -70°C in order to conserve all the activity of
this short-lived enzyme. We also modified the assessment
of protein concentration in the supernatants to eliminate
the influence of dithiothreitol on the final results. DTT
has an ability to reduce copper and interfere with the
standard protein assays. Tissue handling and storage are
important factors in the observed variability of ODC
measurements. The median ODC activities in normal
tissues were similar in the upper and lower GI tract,
although we recorded wide ranges within the studied
groups. Significantly higher values characterized various
premalignant conditions, and the highest activity was
observed in confirmed cancers. However, because of
overlapping results our measurements could not
differentiate between these conditions. In other words,
high activities did not always indicate premalignancy or
malignancy and low values could not exclude increased
neoplastic potential. In addition, no correlation was found
between ODC activity and the degree of dysplasia in the
colonic adenomas.
The exact mechanism of increased activity in
dysplastic tissue remains unknown. Higher ODC values
in the active phase of extensive ulcerative colitis (as
compared to remission) might be caused by more icreased
regenerative processes in the colonic epithelium, rather
than by increased neoplastic potential. We observed no
differences within the stomach as far as the type of
inflammation is concerned.
To summarize, we have identified differences in
mucosal ornithine decarboxylase activity between control
cases and many disease states. No significant differences
have been shown, however, between premalignant and
malignant conditions affecting the stomach, duodenum or
colon. The degree of histological abnormality, such as
epithelial dysplasia, did not correspond to the enzyme
activity. The inability to differentiate groups at risk of
gastrointestinal malignancy from cases of confirmed
cancer indicates that ODC bioassay is not a valuable
marker of increased cancer potential.
Prof. Witold Bartnik MD, PhD
Department of Gastroenterology
Medical Center for Postgraduate Education
The Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology
Roentgena 5, 02-781 Warsaw, Poland
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Table II. ODC activity in extensive ulcerative colitis in remission 
and in the active phase of the disease (in pmol/mg protein/h)
Activity of ulcerative Number Median Inrequartile 
colitis range
Remission 9 289 186-345
Active disease 11 526* 399-1098
* p<0.01 compared to median in remission
Table III. ODC activity in colonic adenomas with low and/or medium
grade and high grade dysplasia (in pmol/mg protein/h)
Degree of dysplasia Number Median Inrequartile 
range
Low and/or medium grade 25 1523 835-2786
High grade 16 1423* 624-2564
* p>0.05 compared to median in low and/or medium grade dysplasia
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